Vida Pharmacal develops, markets, and distributes diagnostics and pharmaceuticals designed to treat emerging and neglected diseases for veterinary and human patients. Founded in 2017, the company has developed the first treatment for Chagas disease in canines. Vida Pharmacal is headquartered in Spring Branch, Texas and privately held.
Oral solid dosage form
Point of Care, Serologic Lateral Flow Assays
Oral solid dosage form
Point of Care, Serologic Lateral Flow Assays
Dr. Madigan is the founder of Vida Pharmacal, a human and veterinary pharmaceutical company. The company’s focus is development of novel therapeutics to address emerging parasitic diseases in both humans and animals. Dr. Madigan’s work includes filing the first veterinary drug patent for anti-T. cruzi activity in dogs and conducting pioneering research in studying the curative effects of a drug combination in human heart cells infected with Chagas disease. He is also developing serologic techniques to diagnose T. cruzi infection in dogs.
Dr. Madigan is the principal scientist in the Canine Chagas Treatment Study, Lackland Air Force Base, San Antonio, TX—research into treatment of canine Chagas disease in Unites States Army military working dogs. He is also the director of The Animal Hospital of Smithson Valley in Spring Branch, TX, where he serves as Chief Medical Officer and coordinator for small animal medicine and surgery. He is a member of the Texas Chagas Task Force, Centers for Disease Control, and University of Texas Health Science Center, San Antonio, TX, as the veterinary lead for canine Chagas disease in Texas. The Task Force increases public awareness of Chagas disease by working with healthcare providers, entomologists, marketing, and the public. Dr. Madigan and his family reside in the Texas Hill Country with a pug named Buda, a golden retriever Daisy, and a GSP named Rip.
John joined Vida Pharmacal as CEO in 2022, bringing over 35 years of executive-level experience with start-up biopharmaceutical companies. Prior to joining Vida, John founded Velcision LLC, a highly successful commercialization company providing startup companies with executive leadership and expertise in commercial, regulatory, clinical, manufacturing, and operations. He has a successful track record of building companies, commercial launches, significant revenue generation, and profitability. John’s additional experience includes fund raising and in-licensing and out-licensing products. John previously served as CEO at Cellular Preservation Technologies, ONY Biotech, and Shore Therapeutics. He was senior vice president, Sales & Marketing, at Acorda Therapeutics, where he helped drive the company’s initial public offering (IPO). As a regional director, he played a key role in the commercialization of Genentech in the early days of the biotechnology industry.
Gerard currently serves as the CFO and CBO at Vida Pharmacal Inc., where he leads corporate development, finance, M&A, and global business development activities. Gerard's executive experience spans more than 30 years of success in leading and executing corporate development, finance, merger-and-acquisition, and business development transactions. Throughout his career, he has been responsible for conceiving, developing, and executing strategies and initiatives for driving revenue, growth, competitive marketing position, profits, and shareholder value. Prior to joining Vida, Gerard held progressive senior executive level positions at Pfizer Inc., Acorda Therapeutics, Retrophin, and Kora Healthcare LTD—as well as led startups and consulting companies.